A Phase 2 interventional study of MEDI-546 and MEDI-546 in Systemic Lupus Erythematosus, sponsored by AstraZeneca. Completed at 6 sites in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-03-13.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 17th largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 2, and was the 2nd registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, Belgium, Chile and 7 more countries
Ages 5–17
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
AstraZeneca · Sites in United States, Canada, France and 6 more countries
Ages 18–70
AstraZeneca · Sites in United States
Ages 18–130 · Women only
By country, each count listing its studies:
anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2012.
This study's enrollment of 17 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 159 across the 20 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 5 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
46 studies in Lupus Erythematosus, Systemic by AstraZeneca: 19 open now, 25 under way, 6 of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 24th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2012, is one of 9 in phase 2, and was the 7th registered.
AstraZeneca’s Lupus Erythematosus, Systemic studies by the year they started, since 2008.
4 of the studies testing anifrolumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05440422National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD | 2027-08-01 |
| NCT06594068AstraZenecaProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users | 2027-08-31 |
| NCT07913919University of CambridgeEffect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, from their registry updates:
Among AstraZeneca’s 46 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEDI-546 in Japanese SLE patients.
A phase 2, multicenter, open-label, dose-escalation study to evaluate the safety and tolerability of intravenous dose of MEDI-546, a human monoclonal antibody directed against type I interferon receptor (IFNAR), in Japanese subjects with active systemic lupus erythematosus (SLE)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MEDI-546 100 mg IV
Drug: MEDI-546
MEDI-546 300 mg IV
Drug: MEDI-546
MEDI-546 1000 mg IV
Drug: MEDI-546
Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.
Overall Summary of Adverse Events
Time frame: Stage I (up to 48 weeks)
Pharmacokinetic Parameters of MEDI-546 After Single Dose: Cmax
Time frame: Pre-dose and within 30 minutes after end of infusion on Day 1, Days 2, 8, 15, and 22, and pre-dose on Day 29
Pharmacokinetic Parameters of MEDI-546 After Single Dose: AUClast
Time frame: Pre-dose and within 30 minutes after end of infusion on Day 1, Days 2, 8, 15, and 22, and pre-dose on Day 29
Anti-drug Antibody (ADA)
MEDI-546 antibody detection measured by electrochemiluminescence (ECL).
Time frame: Stage I (up to Week 48)
| Milestone | MEDI-546 100 mg IV | MEDI-546 300 mg IV | MEDI-546 1000 mg IV |
|---|---|---|---|
| Started | 6 | 5 | 6 |
| Completed | 4 | 3 | 3 |
| Not completed | 2 | 2 | 3 |
| Withdrew: Withdrawal by subject | 2 | 2 | 3 |
| Milestone | MEDI-546 100 mg IV | MEDI-546 300 mg IV | MEDI-546 1000 mg IV |
|---|---|---|---|
| Started | 4 | 3 | 2 |
| Completed | 3 | 3 | 2 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| ug/mL | MEDI-546 100 mg IV | MEDI-546 300 mg IV | MEDI-546 1000 mg IV |
|---|---|---|---|
| Pharmacokinetic Parameters of MEDI-546 After Single Dose: Cmax | 41.1 ± 27.6 | 75.1 ± 12.5 | 254.8 ± 20.7 |
| Participants | MEDI-546 100 mg IV | MEDI-546 300 mg IV | MEDI-546 1000 mg IV |
|---|---|---|---|
| Any AE | 6 | 5 | 6 |
| Any AE of grade 3 or higher | 1 | 1 | 1 |
| Any AE with outcome=death | 0 | 0 | 0 |
| Any SAE | 2 | 2 | 3 |
| Any AE leading to discontinuation of IP | 2 | 1 | 1 |
| Any causally related AE | 5 | 4 | 4 |
| Any other significant AE | 0 | 0 | 0 |
| ug.day/mL | MEDI-546 100 mg IV | MEDI-546 300 mg IV | MEDI-546 1000 mg IV |
|---|---|---|---|
| Pharmacokinetic Parameters of MEDI-546 After Single Dose: AUClast | 221.5 ± 18.8 | 666.5 ± 36.8 | 3151.9 ± 14.6 |
MEDI-546 antibody detection measured by electrochemiluminescence (ECL).
| Participants | MEDI-546 100 mg IV | MEDI-546 300 mg IV | MEDI-546 1000 mg IV |
|---|---|---|---|
| Positive | 1 | 1 | 1 |
| Negative | 5 | 4 | 5 |
Collected over Stage I: 337 to 422 days. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MEDI-546 100 mg IV | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| MEDI-546 300 mg IV | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| MEDI-546 1000 mg IV | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Event | MEDI-546 100 mg IV | MEDI-546 300 mg IV | MEDI-546 1000 mg IV |
|---|---|---|---|
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 0/6 | 1/5 | 1/6 |
| CellulitisInfections and infestations | 0/6 | 1/5 | 0/6 |
| LymphadenopathyBlood and lymphatic system disorders | 0/6 | 0/5 | 1/6 |
| Acute abdomenGastrointestinal disorders | 1/6 | 0/5 | 0/6 |
| Chest painGeneral disorders | 0/6 | 0/5 | 1/6 |
| Cerebral infarctionNervous system disorders | 1/6 | 0/5 | 0/6 |
| AbortionPregnancy, puerperium and perinatal conditions | 0/6 | 0/5 | 1/6 |
| Event | MEDI-546 100 mg IV | MEDI-546 300 mg IV | MEDI-546 1000 mg IV |
|---|---|---|---|
| NsopharyngitisInfections and infestations | 3/6 | 1/5 | 4/6 |
| Herpes zosterInfections and infestations | 0/6 | 2/5 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 2/6 | 0/5 | 1/6 |
| GastroenteritisInfections and infestations | 2/6 | 0/5 | 0/6 |
| Abdominal pain upperGastrointestinal disorders | 1/6 | 1/5 | 2/6 |
| HypertensionVascular disorders | 2/6 | 0/5 | 0/6 |
| BronchitisInfections and infestations | 1/6 | 1/5 | 0/6 |
| InfluenzaInfections and infestations | 1/6 | 1/5 | 0/6 |
| NauseaGastrointestinal disorders | 0/6 | 1/5 | 1/6 |
| HeadacheNervous system disorders | 1/6 | 1/5 | 1/6 |
| Age, Continuous(years) | MEDI-546 100 mg IV | MEDI-546 300 mg IV | MEDI-546 1000 mg IV | Total |
|---|---|---|---|---|
| Mean | 43 ± 12 | 34 ± 11 | 37 ± 10 | 38 ± 11 |
| Sex/Gender, Customized(male/female) | MEDI-546 100 mg IV | MEDI-546 300 mg IV | MEDI-546 1000 mg IV | Total |
|---|---|---|---|---|
| Male | 0 | 1 | 0 | 16 |
| Female | 6 | 4 | 6 | 1 |
Ran from Apr 2012 to primary completion in Aug 2014, 27 months.
Results were first posted in Mar 2019, 4 years 6 months after primary completion.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 27 months is below that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anifrolumab
Lupus Erythematosus, Systemic →